Functional diversity increases the efficacy of phage combinations

Rosanna C. T. Wright¹,²,³*, Ville-Petri Friman², Margaret C. M. Smith² and Michael A. Brockhurst¹

Abstract
Phage therapy is a promising alternative to traditional antibiotics for treating bacterial infections. Such phage-based therapeutics typically contain multiple phages, but how the efficacy of phage combinations scales with phage richness, identity and functional traits is unclear. Here, we experimentally tested the efficacy of 827 unique phage combinations ranging in phage richness from one to 12 phages. The efficacy of phage combinations increased with phage richness. However, complementarity between functionally diverse phages allowed efficacy to be maximized at lower levels of phage richness in functionally diverse combinations. These findings suggest that phage functional diversity is the key property of effective phage combinations, enabling the design of simple but effective phage therapies that overcome the practical and regulatory hurdles that limit development of more diverse phage therapy cocktails.

INTRODUCTION
Bacterial killing by lytic phages regulates bacterial turnover in microbial communities, influencing bacterial community dynamics in both environmental and clinical settings [1, 2]. Phage diversity is predicted to exceed that of their hosts by up to 10 times [3], and may vary between communities just metres apart [4]. A survey of phages able to infect Pseudomonas aeruginosa, a commonly multi-drug-resistant opportunistic pathogen [5], across four continents identified seven distinct phage groups with lytic activity against 87% of clinical bacterial strains tested [6], and novel phage taxa are continually being discovered [7, 8]. This diversity of phages offers a promising alternative to antibiotics for treating bacterial infection where rates of antibiotic resistance are rapidly rising [9–11]. Multiple phages are often combined for therapeutic use to improve the range of hosts which can be targeted. However, more diverse combinations pose greater regulatory hurdles as individual phages and interaction effects must be assessed [12–14]. While developing efficient, low-diversity phage combinations would be highly practical, it is unclear which rationale one should use to design such combinations.

The relationship between biodiversity and ecosystem functioning (i.e. the collective activity of a community) is usually positive [15]. Increasing species richness has been shown to improve the function of microbial communities by two distinct mechanisms [16, 17]. First, if species perform different ecological roles, then greater species richness can deliver higher community-level performance due to functional complementarity, through filling more of the available niche space [16, 18]. Second, more diverse communities are more likely to contain highly performing taxa simply by chance, leading to a positive relationship between diversity and function due to species identity effects [16, 17]. On the other hand, functional redundancy among species in a community can lead to diminishing returns of further increasing species richness, resulting in a saturating relationship between richness and function [19–21]. These counteracting effects suggest that high killing efficacy could be attained by low-richness phage combinations, provided that these contain functionally different and non-redundant phages. Such combinations would have practical benefits in terms of reducing the manufacturing and regulatory challenges posed by higher order phage combination therapies [13, 14, 22].

For phages, lytic infection of a bacterial host depends on adsorption to the host outer membrane and evasion of host phage defence systems once within the cell [23]. Binding to specific bacterial cell-surface receptors for adsorption is therefore a key functional trait for phages. Phage combinations targeting higher numbers of receptors may be more efficacious by virtue of their functional diversity reducing...
competition among phages for shared adsorption sites. Such phage combinations could also limit resistance evolution via cell surface modification since this would be likely to require multiple mutations [24–26], which often impose additive fitness costs [27].

By applying the principles of biodiversity–ecosystem functioning to the design of phage therapies, we sought to determine the relative importance of phage species richness, functional diversity and interaction effects on the efficacy of phage combinations. We used 12 P. aeruginosa phages including phages targeting either lipopolysaccharide (LPS) or Type IV pilus (T4P) for adsorption to create 827 unique phage combinations with differing levels of species richness and degrees of functional diversity. These combinations included all possible single, pairwise and three-member communities, 264 different four- and six-member communities, and the full 12-member community. We show that phage richness had a saturating relationship with efficacy (defined as the suppression of bacterial growth), and that highly efficacious but low-richness phage combinations could be designed provided that they had high functional diversity, i.e. the constituent phages targeted multiple distinct adsorption receptors. Together, these results suggest that ecological complementarity plays a key role in determining the efficacy of phage combinations.

**METHODS**

**Phage combination design and community assembly**

A panel of 12 lytic P. aeruginosa phages were used to build phage combinations of varying phage community species richness. The adsorption receptors of all phages has previously been characterized [28]; four phages adsorb via T4P and eight via LPS. In total, we assembled 827 different phage combinations, ranging from single phage (12), all possible two- and three-member communities (66 and 220 respectively), a random partition of four- and six-member communities (264 of each), to the full 12-member community. A random partition design was used to select four- and six-phage communities which equally represent all phage strains across both richness levels (as described previously [29]).

Phage stocks were amplified to equal densities (~8.9×10^{10}±1.6×10^{10} p.f.u. ml^{-1}) using the susceptible bacterial host P. aeruginosa PAO1, isolated by filtration (0.22 µm) and stored at 4℃. To limit human error, master plates of phage communities were assembled in deep 96-well plates using a liquid handling robot (epMotion 5070; Eppendorf) in triplicate. Equal volumes (and densities) of each phage were added to give a final volume of 120 µl per phage community.

**Measuring the efficacy of phage combinations**

We determined the efficacy of phage combinations as their ability to suppress growth of the susceptible host, P. aeruginosa PAO1. Bacterial replicates were inoculated from three single colonies into 6ml KB medium and grown overnight at 37℃ with shaking at 180 r.p.m., before diluting 100-fold into assay plates containing 120 µl of KB. Phage communities were transferred from the master plates (15 µl per well) to give a multiplicity of infection (m.o.i.) of approximately 100 phages per bacterial cell (actual m.o.i. ~80±20.2 with initial bacterial density of ~9.6×10^{10}±1.1×10^{10}). Optical density (absorbance at 600 nm; Abs_{600}) was measured immediately, then after static incubation for 24h at 37℃. Phage combination efficiency was measured as the reduction in bacterial growth in the presence relative to the absence of phage, as 'Efficacy' (Equation 1; [30]).

Equation (1)

\[
Efficacy = 1 - \frac{Abs_{600}(t=24h) - Abs_{600}(t=0h)}{Abs_{600}(t=24h)}
\]

Efficacy measurements were taken at 24 h based on previous data [28, 31] and pilot experiments using a random subset of diverse phage communities (at species richness levels of between one and 12 phages; Fig. S1, available in the online version of this article). These showed that at 0–12 h bacterial growth is almost completely suppressed by almost all phages and combinations. However, between 12 and 24 h for some phages and phage combinations, bacteria begin to grow, probably due to spontaneous mutations providing phage resistance (see [28, 31] for characterization of spontaneous phage resistance mutations within this system). Taking the efficacy measurement at 24 h thus differentiates phages and phage combinations that effectively suppress both growth and the emergence of resistance, from those that suppress growth initially but against which resistance does eventually emerge.

For each phage combination, the phage with the highest independent Efficacy value was considered as the best constituent phage (i.e. measured when Diversity=1; matched by replicate to the phage combination). These values were used to calculate transgressive overyielding, D_{max} (Eqn 2 [32]), which is a measure that describes the efficacy of a community relative to its most efficient member, such that a value of 0 indicates equal efficacy and values above 0 indicate that the community was more effective.

Equation (2)

\[
D_{max} = \frac{Efficacy_{combination}-Efficacy_{best}}{Efficacy_{best}}
\]

**Statistical analysis**

The relationship between phage strain richness and efficacy was analysed using a previously described linear model method designed to separate significant factors affecting biodiversity–ecosystem functioning [29]. Phage richness and functional diversity (i.e. number of different receptor targets) were included as interacting main effects, alongside other main effects of receptor targets (i.e. presence of LPS- and/ or T4P-targeting phages), phage identity (including pairwise and higher order interactions between phages as separate main effects) and non-linear effects of phage richness. Due to the saturating relationship between phage richness and efficacy, we also fitted a non-linear asymptotic exponential model to the data. Model parameters were determined using
the non-linear least squares function in R [33], and compared to equivalent linear models using the Akaike information criterion (AIC).

The effects of richness, functional diversity and phage identity on transgressive overyielding were also analysed using a linear model. Significant interaction terms between functional diversity and richness, functional diversity and phage identity, and pairwise interactions between phages were included in the model. Here, receptor target was excluded from the model as it was not significant. Non-linear richness was included as an explanatory variable, and best fits of regression models (linear versus decaying exponential model) were assessed by AIC to fit regression curves to the plotted data. All analyses were performed in R (version 3.5.2 [33]).

RESULTS

Diminishing returns of increasing phage richness on phage combination efficacy

The efficacy of phage combinations, measured as their ability to reduce bacterial growth, increased with phage community richness (i.e. number of phage strains). However, phage richness explained only 30% of the variation in efficacy (Fig. 1; linear model efficacy: $F_{1,5740} = 2497, P < 0.0001, R^2 = 0.303$). Non-linear models explained a greater proportion of the variation: the relationship between richness and efficacy was best explained by an asymptotic exponential model where the asymptote was reached when bacterial growth was completely suppressed (Fig. 1; AIC linear model = 205; AIC asymptotic model = (−)1190). This suggests that there were low-richness phage combinations that were as effective as the highest richness phage combination, whose efficiency could not be improved with additional phages, probably due to functional redundancy among the constituent phage strains.

Increased phage functional diversity improves phage combination efficacy

Including functional diversity (FD), in terms of the receptor targeted by the phage, in the model explained substantially more of the observed variation in efficacy: phage functional diversity and strain richness together accounted for ~70% of the variation in efficacy (Fig. 2; linear model efficacy, main effects of phage diversity and functional diversity and their interaction: $F_{3,5738} = 4476, P < 0.0001, R^2 = 0.701$). Phage pairs with functional diversity outperformed phage pairs targeting LPS or T4P alone (LPS + T4P vs LPS only, species richness=2: $F_{1,358} = 633, P < 0.0001$; LPS + T4P vs T4P only, species richness=2: $F_{1,226} = 10.78, P = 0.0012$). Phages targeting T4P contributed more to efficacy than LPS-binding phages, such that combinations containing only T4P-binding phages outperformed combinations containing only LPS-binding phages (Fig. 2a, b; linear model efficacy, coefficient of T4P-binding phages: $t = 11.16, P < 0.0001$; coefficient of LPS-binding phages: $t = (−)24.57, P < 0.001$). Functionally diverse combinations containing phages targeting both LPS and T4P receptors showed a saturating relationship between efficacy and phage richness and completely suppressed bacterial growth at
biodiversity–ecosystem function relationships, we compared the relative contributions of phage richness, phage identity and functional diversity in determining the efficacy of phage combinations. We observed a saturating relationship between phage richness and efficacy, consistent with diminishing returns of increasing richness due to functional redundancy among phages at higher richness levels. Correspondingly, phage combinations with higher functional diversity, in terms of the number of cell surface receptors targeted for phage adsorption, were more effective at suppressing bacterial growth and were able to do so at lower levels of phase richness (e.g. two or three phages) than low functional diversity combinations. Functionally diverse phage combinations targeting different adsorption receptors displayed higher transgressive overyielding and stronger complementarity at low levels of phase richness, achieving up to three-fold higher efficacy than their best constituent phage even for combinations of just two phages. Together, our data suggest that functional diversity is the most important determinant of the efficacy of phage combinations.

By maximizing functional diversity, phage combinations can be optimized for bacterial killing at low strain diversity, thus reducing the regulatory hurdles of preparing more complex therapeutic combinations [13, 14, 22]. Functional complementarity between phages targeting different adsorption receptors is likely to have two key benefits: first, decreased competition for binding sites to adsorb to the bacterial cell may lead to increased lysis and second, functionally diverse phage combinations are more likely to suppress resistance evolution. In this study, the efficacy of phage combinations was measured 24 h post-exposure to phages, which is sufficiently long to permit the evolution of phage resistance if this is possible against the phage combination [28]. The majority of resistance mutations arising against our phage panel target the genes encoding the bacterial cell surface receptors (LPS and T4P [28, 31]), and as such, promote cross-resistance to alternative phages which adsorb to the same receptor. However, cross-resistance may not be absolute, for example if phages target different binding sites on the same receptor. In contrast, even weak resistance to a functionally diverse phage combination is likely to require multiple independent resistance mutations (e.g. modification of each adsorption target [31]), which will co-occur in the same cell with far lower probability.

In addition to increasing efficacy against a single bacterial genotype, higher functional diversity may also prove beneficial in more complex scenarios. For example, functionally diverse phage combinations are likely to be able to target a broader diversity of bacterial genotypes. This could be particularly relevant in the treatment of chronic infections, where the bacterial populations typically undergo extensive evolutionary diversification (e.g. in response to host–pathogen interactions) [34, 35]. This can lead to altered expression of common phage receptor targets, including modification and even loss of LPS components and T4P [36–38], which

**DISCUSSION**

To enable rational design of phage therapy combinations, it is important to understand the key factors which determine a phage combination’s efficacy in suppressing bacterial growth. Applying concepts from the analysis of ecological lower levels of phase diversity than combinations targeting only a single receptor (Fig. 2c). Phage identity accounted for only ~3% of the remaining variation in efficacy (linear model for the best constituent phage as a monoculture. Phage combinations either target one receptor [FD=1; (a) LPS binding; (b) T4P binding] or include phages targeting LPS and targeting T4P [FD=2; (c) LPS + T4P binding]. Mean values (±SD) are shown in black, with raw data in grey to show the distribution of data points; regression lines were fit either as a linear model (a, b) or an exponential degradation model (c).
can reduce susceptibility to phage infection [39, 40]. Essentiality of different cell-surface receptors across environments may explain differences in observed efficacy between phages targeting different adsorption receptors. Phage combinations targeting a broader range of cell surface receptors will be more likely to be able to infect and clear such host-adapted bacterial populations.

In this study, functional phage diversity was limited to two cell surface receptor targets, but further increases in the diversity of receptors targeted by phage combinations are likely to lead to further increases in their efficacy. Examples of other *P. aeruginosa* cell surface receptors used for phage adsorption include outer membrane porins [41] and other membrane-anchored proteins such as TonB-dependent receptors, which can be involved in iron-siderophore uptake [24, 42]. Our findings are limited by the use of a single host strain, which expresses surface receptors for all phages used in this study, and in which the phages were amplified such that any active restriction-modification system would be redundant. To understand how functional diversity is likely to influence phage therapy clinically, it will be necessary to investigate the efficacy of phage combinations against a more diverse panel of bacterial host strains. This approach would take into account strain differences in receptor expression and the presence of additional post-infection resistance mechanisms, such as CRISPR-Cas [43] and other phage defence systems. Inducible resistance mechanisms may be preferentially selected *in vivo* because of their lower fitness costs compared to surface receptor modification mutations [44]. Unlike surface modification resistance mutations, CRISPR-mediated resistance is likely to promote different cross-resistance interactions between phages mediated by their genetic similarity rather than their receptor target for adsorption. This suggests that whilst functional diversity of phage strains is necessary to limit the evolution of cross-resistance via surface modification, maximizing genetic diversity could be important to limit cross-resistance via sequence-based resistance mechanisms such as CRISPR-Cas, restriction modification or other recently discovered phage defence systems [45].

To conclude, our findings suggest that maximizing functional diversity is a simple and effective rule for designing high-efficacy, low-richness phage combinations overcoming the regulatory hurdles associated with preparation of complex phage cocktails.

Funding information
This work was supported by an ACCE DTP PhD Studentship to R.C.T.W. funded by the Natural Environment Research Council (NE/L002450/1, Studentship 1517986) and a research grant from the Biotechnology and Biological Sciences Research Council (BB/T014342/1) to M.A.B., V.F. and R.C.T.W.

Acknowledgements
We thank Matti Jalasvuori for providing us with phage strains.

Conflicts of interest
The authors declare that there are no conflicts of interest.

References
1. Harrison F. Microbial ecology of the cystic fibrosis lung. *Microbiology (Reading)* 2007;153:917–923.
2. Levin BR, Bull JJ. Population and evolutionary dynamics of phage therapy. *Nat Rev Microbiol* 2004;2:166–173.
3. Clokie MR, Millard AD, Letarov AV, Heaphy S. Phages in nature. *Bacteriophage* 2011;1:31–65.
4. Frederickson CM, Short SM, Suttle CA. The physical environment affects cyanophage communities in British Columbia inlets. *Microb Ecol* 2003;46:348–357.
5. Breidenstein EBM, de la Fuente-Nuñez C, Hancock REW. *Pseudomonas aeruginosa*: all roads lead to resistance. *Trends Microbiol* 2011;19:419–426.
6. Ceyssens P-J, Noben J-P, Ackermann H-W, Verhaegen J, De Vos D, et al. Survey of *Pseudomonas aeruginosa* and its phages: de novo peptide sequencing as a novel tool to assess the diversity of worldwide collected viruses. *Environ Microb* 2009;11:1303–1313.
7. Azeredo J, Martins LF, Lombardi KC, Antunes LP, de Souza APS, et al. Three novel *Pseudomonas* phages isolated from composting provide insights into the evolution and diversity of tailed phages. *BMC Genomics* 2017;18:346.
8. Sepúlveda-Robles O, Kameyama L, Guarnerlos G. High diversity and novel species of *Pseudomonas aeruginosa* bacteriophages. *Appl Environ Microb* 2012;78:4510–4515.
9. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. *Future Microbial* 2013;8:769–783.
10. Pires DP, Vilas Boas D, Sillankorva S, Azeredo J. Phage therapy: a step forward in the treatment of *Pseudomonas aeruginosa* infections. *J Virol* 2015;89:7449–7456.
11. World Health Organization. Antimicrobial resistance global report on surveillance: 2014 summary. 2014. https://apps.who.int/iris/handle/10665/112647
12. Pirnay J-P, Blasdel BG, Bretaeudeau L, Buckling A, Chanishvili N, et al. Quality and safety requirements for sustainable phage therapy products. *Pharm Res* 2015;32:2173–2179.
13. Merabishvili M, Pirnay J-P, De Vos D. Guidelines to compose an ideal bacteriophage cocktail. In: Azeredo J and Sillankorva S (eds). *Bacteriophage Therapy: From Lab to Clinical Practice*. New York, NY; Springer New York: , pp 99–110.
14. Verbeken G, Pirnay J-P, De Vos D, Jennes S, Zizi M, et al. Optimizing the european regulatory framework for sustainable bacteriophage therapy in human medicine. *Arch Immunol Ther Exp* 2012;60:161–172.
15. Tilman D, Isbell F, Cowles JM. Biodiversity and ecosystem functioning. *Annu Rev Ecol Evol Syst* 2014;45:471–493.
16. Bell T, Newman JA, Silverman BW, Turner SL, Lilley AK. The contribution of species richness and composition to bacterial services. *Nature* 2005;436:1157–1160.
17. Evans R, Alessi AM, Bird S, McQueen-Mason SJ, Bruce NC, et al. Defining the functional traits that drive bacterial decomposer community productivity. *ISME J* 2017;11:1680–1687.
18. Salles JF, Poly F, Schmid B, Le Roux X. Community niche predicts the functioning of denitrifying bacterial assemblages. *Ecology* 2009;90:3324–3332.
19. Petchey OL, Gaston KJ. Functional diversity: back to basics and looking forward. *Ecol Lett* 2006;9:741–758.
20. Tilman D, Knops J, Wedin D, Reich P, Ritchie M, et al. The influence of functional diversity and composition on ecosystem processes. *Science* 1997;277:1300–1302.
21. Yin B, Crowley D, Sparovek G, De Melo WJ, Borneman J. Bacterial functional redundancy along a soil reclamation gradient. *Appl Environ Microb* 2000;66:4361–4365.
22. Brussow H. What is needed for phage therapy to become a reality in Western medicine? *Virology* 2012;436:138–142.
23. Labrie SJ, Samson JE, Moinneau S. Bacteriophage resistance mechanisms. *Nat Rev Microbiol* 2010;8:317–327.
24. Betts A, Gray C, Zelek M, MacLean RC, King KC. High parasite diversity accelerates host adaptation and diversification. Science 2018;360:907–911.

25. Gurney J, Aldakak L, Betts A, Gougat-Barbera C, Poisot T, et al. Network structure and local adaptation in co-evolving bacteria-phage interactions. Mol Ecol 2017;26:1764–1777.

26. Tanji Y, Shimada T, Yoichi M, Miyanaga K, Hori K, et al. Toward rational control of Escherichia coli O157:H7 by a phage cocktail. Appl Microbiol Biotechnol 2004;64:270–274.

27. Koskella B, Lin DM, Buckling A, Thompson JN. The costs of evolving resistance in heterogeneous parasite environments. Proc R Soc B 2011;279:1896–1903.

28. Wright RCT, Friman V-P, Smith MCM, Brockhurst MA. Cross-resistance is modular in bacteria-phage interactions. PLoS Biol 2018;16:e2006057.

29. Bell T, Lilley AK, Hector A, Schmid B, King L, et al. A linear model method for biodiversity-ecosystem functioning experiments. Am Nat 2009;174:836–849.

30. Poullain V, Gandon S, Brockhurst MA, Buckling A, Hochberg ME. The evolution of specificity in evolving and coevolving antagonistic interactions between a bacteria and its phage. Evolution 2008;62:1–11.

31. Wright RCT, Friman V-P, Smith MCM, Brockhurst MA. Resistance evolution against phage combinations depends on the timing and order of exposure. mBio 2019;10:e01652-19.

32. Loreau M. Separating sampling and other effects in biodiversity experiments. Oikos 1998;82:600.

33. Core Team R. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2018. https://www.R-project.org/

34. Mowat E, Paterson S, Fothergill JL, Wright EA, Ledson MJ, et al. Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. Am J Respir Crit Care Med 2011;183:1674–1679.

35. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A 2006;103:8487–8492.

36. Hancock RE, Mutharia LM, Chan L, Darveau RP, Speert DP, et al. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect Immun 1983;42:170–177.

37. Huse HK, Kwon T, Zlosnik JEA, Speert DP, Marcotte EM, et al. Parallel evolution in Pseudomonas aeruginosa over 39,000 generations in vivo. mBio 2010;1:e00199-10.

38. Mahenthiralingam E, Campbell ME, Speert DP. Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect Immun 1994;62:596–605.

39. Friman V-P, Ghoul M, Molin S, Johansen HK, Buckling A, et al. Pseudomonas aeruginosa adaptation to lungs of cystic fibrosis patients leads to lowered resistance to phage and protist enemies. PLoS ONE 2013;8:e75380.

40. Mattila S, Ruotsalainen P, Jalasvuori M. On-demand isolation of bacteriophages against drug-resistant bacteria for personalized phage therapy. Front Microbiol 2015;6:1271.

41. Chan BK, Sistrom M, Wertz JE, Kortright KE, Narayan D, et al. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep 2016;6:26717.

42. Poole K, Zhao Q, Neshat S, Heinrichs DE, Dean CR. The Pseudomonas aeruginosa tonB gene encodes a novel TonB protein. Microbiology 1996;142:1449–1458.

43. Horvath P, Barrangou R. CRISPR/Cas, the immune system of bacteria and archaea. Science 2010;327:167–170.

44. Westra ER, van Houte S, Oyesiku-Blakemore S, Makin B, Broniewski JM, et al. Parasite exposure drives selective evolution of constitutive versus inducible defense. Curr Biol 2015;25:1043–1049.

45. Dornon S, Melamed S, Ofir G, Leavitt A. Lopatina A, et al. Systematic discovery of antiphage defense systems in the microbial pan-genome. Science 2018;359.

Edited by: D. Grainger and M. Van Der Woude

---

**Five reasons to publish your next article with a Microbiology Society journal**

1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around the world.
4. 80% of our authors rate our submission process as ‘excellent’ or ‘very good’.
5. Your article will be published on an interactive journal platform with advanced metrics.

Find out more and submit your article at microbiologyresearch.org.